Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387033 | 0.87 | HTR1D (0.46) | OPRM1OPRK1OPRL1CCR2DRD2 | |
| SCHEMBL5359211 | 0.87 | CCR2 (0.53) | OPRM1OPRK1OPRL1CCR2HSD11B1 | |
| SCHEMBL5354238 | 0.83 | HSD11B1 (0.46) | OPRM1OPRK1OPRL1CCR2HSD11B1 | |
| SCHEMBL14387087 | 0.83 | CCR2 (0.54) | CCR2DRD2HTR1D | |
| SCHEMBL14386503 | 0.81 | CCR2 (0.67) | CCR2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL5359774 | 0.81 | CCR2 (0.67) | CCR2HTR1AHTR7DRD2HTR2A | |
| SCHEMBL5362149 | 0.81 | HSD11B1 (0.54) | OPRM1OPRK1OPRL1HSD11B1HTR1A | |
| SCHEMBL14387029 | 0.81 | HTR1D (0.46) | OPRM1OPRK1OPRL1CCR2HSD11B1 | |
| SCHEMBL5350309 | 0.80 | HSD11B1 (0.45) | OPRM1OPRK1OPRL1CCR2HSD11B1 | |
| SCHEMBL5359770 | 0.79 | CCR2 (0.47) | OPRM1OPRK1OPRL1CCR2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | OPRM1 513/4885OPRK1 167/4885OPRL1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.